Strategic Initiative

Slingshot members are tracking this corporate initiative:

Lilly And Boehringer Ingelheim Announce Clinical Trial Collaboration In Metastatic Breast Cancer

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
LLY Community voting in process
Boehringer Ingelheim Community voting in process

Additional Information

Additional Relevant Details Based on the Phase 1b trial results, the collaboration has the potential to expand to Phase 2 trials in patients with HR+, HER2- mBC and other solid tumors. Enrollment is scheduled to begin in late 2016, and Boehringer Ingelheim will be the sponsor of the study program.

Lilly's abemaciclib is designed to block the growth of cancer cells by specifically inhibiting CDK 4 and CDK 6. In many cancers, uncontrolled cell growth arises from a loss of control in regulating the cell cycle due to increased signaling from CDK 4 and CDK 6. Boehringer Ingelheim's BI 836845 is an IGF ligand-neutralizing antibody that binds to both IGF-1 and IGF-2 preventing activation of the respective receptor resulting in decreased growth-promoting signaling, which may decrease tumor growth. In a Phase 1b/2 trial BI 836845 has shown promising preliminary efficacy and good clinical safety in combination with everolimus and exemestane in patients with HR+ mBC.1The rationale for the collaboration is based upon the hypothesis that these two agents, in combination, could offer a more complete pathway interference and could potentially prolong cell cycle arrest. For HR+, HER2- mBC patients, this could translate to a reversal of resistance to hormone therapy.
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
Jul 13, 2016
Projected Implementation:
Q3, 2016
Relevance Tracked Until:
Q2, 2017
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Metastatic Breast Cancer, Igf Mab Bi 836845, Insulin-like Growth Factor, Cyclin-dependent Kinase, Cdk 6 Inhibitor, Breast Cancer, Abemaciclib, Bi 836845